Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer
2000
Tumour prothymosin alpha content as a marker for breast cancer prognosis
Sample size: 210
publication
Evidence: moderate
Author Information
Author(s): Magdalena C, Dominguez F, Loidi L, Puente J L
Primary Institution: Hospital Xeral de Galicia, Spain
Hypothesis
Tumour prothymosin α (PTA) levels can identify breast cancer patients at high risk for distant metastasis.
Conclusion
High levels of tumour PTA are associated with worse outcomes in breast cancer patients.
Supporting Evidence
- Tumour PTA levels were significantly associated with disease-free survival and overall survival.
- Patients with low or moderate PTA levels had a decreased rate of tumour recurrence.
- Patients with high PTA levels had a relative risk of dying 2.1 times greater than those with low or moderate levels.
Takeaway
This study found that breast cancer patients with low or moderate levels of a protein called prothymosin alpha have a better chance of surviving than those with high levels.
Methodology
The study analyzed tumour PTA levels and their association with disease-free survival and overall survival in 210 female patients with ductal carcinoma.
Participant Demographics
210 consecutive female patients with ductal carcinoma.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website